ICH Proposals Would Streamline Analytical Technology Adoption
Executive Summary
ICH regulatory members will seek input on guidelines that bring quality-by-design concepts to the development and evolution of the analytical methods required for release of drug products.
You may also be interested in...
Drug Makers Look To Simplify Application Process With New ICH Guidance On Platform Methods
As ICH member countries prepare to implement Q2(R1)/Q14 guidelines, industry is focusing on provisions in both for platform analytical procedures, which applicants for drug approvals and biologics licenses could use to reduce method validation requirements. Pfizer undertook the first commercial application of the platform analytical approach, which is widely used in development.
The ICH Plans To Propose Q14 Guideline On Analytical Testing In January
The ICH is expected to release for public comment early next year its draft Q14 guideline establishing a lifecycle approach for analytical testing, as well as a Q2(R2) guideline to add some newer analytical methods.
Industry Prepares For Emerging ICH Q14 Quality-By-Design Approach To Analytical Methods
EU industry group advises drug makers on how to prepare for enhanced quality-by-design approaches to analytical methods that the International Conference on Harmonization plans to propose early next year. ICH recently shared its concept, which involves revising its Q2(R2) guideline and adding a Q14 guideline, and its business plan for establishing the guidance.